In this episode, we survey the evolving landscape of virtual clinical trials (VCTs), also known as in silico trials, which leverage computational modeling and artificial intelligence to predict therapeutic outcomes and optimize drug development. We categorize current methodologies into five distinct approaches: statistical synthetic control arms, mechanistic Quantitative Systems Pharmacology (QSP) and Physiologically Based Pharmacokinetic (PBPK) models, dynamic AI-driven Digital Twins, and microphysiological systems. The analysis examines the mathematical foundations of virtual patient generation—including Bayesian inference and sensitivity analysis—while critically assessing the “reality gap” between model predictions and complex biological heterogeneity. While VCTs have achieved regulatory milestones in specific contexts, such as rare diseases and dose optimization, challenges remain with parameter identifiability and validation. We discuss how recent advances in AI foundation models and causal inference are bridging these limitations, forecasting a phased adoption timeline where in silico methods increasingly augment human trials in the near term (2026–2028) before potentially replacing early-phase safety assessments in the next decade. Produced by Dr. Jake Chen.